Friday, August 01, 2025 10:57:16 AM
IXHL, isn't it a good news? Here:
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
2025-07-31 08:00 ET - News Release
MELBOURNE, Australia, July 31, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) announced, in response to recent questions it received from a number of its stockholders, that it does not presently intend to use the full capacity available under its at the market offering program (the “ATM”) in the near-term. As previously disclosed in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission on July 24, 2025, the Company is under no obligation to issue any shares of its common stock pursuant to the ATM and any utilisation of the ATM will be at the discretion of the Company, taking into account prevailing market conditions and strategic priorities. The Company’s general practice is to make use of the ATM in its discretion, but in limited amounts compared to the then-present daily trading volume. For example, on July 30, 2025, the Company sold approximately 9.2 million shares of its common stock pursuant to the ATM, which represented only 1.97% of the reported daily trading volume for the day. Prior to yesterday’s activity, the Company had not utilised the ATM facility since July 17. With a strong current cash balance of approximately US$50 million, Incannex is well positioned to advance its portfolio of drug candidates through the next stages of development.
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
2025-07-31 08:00 ET - News Release
MELBOURNE, Australia, July 31, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) announced, in response to recent questions it received from a number of its stockholders, that it does not presently intend to use the full capacity available under its at the market offering program (the “ATM”) in the near-term. As previously disclosed in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission on July 24, 2025, the Company is under no obligation to issue any shares of its common stock pursuant to the ATM and any utilisation of the ATM will be at the discretion of the Company, taking into account prevailing market conditions and strategic priorities. The Company’s general practice is to make use of the ATM in its discretion, but in limited amounts compared to the then-present daily trading volume. For example, on July 30, 2025, the Company sold approximately 9.2 million shares of its common stock pursuant to the ATM, which represented only 1.97% of the reported daily trading volume for the day. Prior to yesterday’s activity, the Company had not utilised the ATM facility since July 17. With a strong current cash balance of approximately US$50 million, Incannex is well positioned to advance its portfolio of drug candidates through the next stages of development.
Recent IXHL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 01:29:02 PM
- Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea • GlobeNewswire Inc. • 05/14/2026 02:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 11:30:31 AM
- Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:30:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 12:00:44 PM
- Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 12:00:23 PM
- Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position • GlobeNewswire Inc. • 03/27/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 12:00:06 PM
- Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research • GlobeNewswire Inc. • 03/25/2026 12:00:00 PM
- Incannex says it holds $75 million in cash with zero debt after financing • IH Market News • 03/18/2026 02:24:59 PM
- Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development • GlobeNewswire Inc. • 03/18/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 12:00:21 PM
- Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 03/17/2026 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/12/2026 08:17:41 PM
- Incannex outlines dose-optimization study for sleep apnea treatment • IH Market News • 03/12/2026 03:42:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:05:33 PM
- Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 03/12/2026 12:05:00 PM
- Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes • GlobeNewswire Inc. • 03/12/2026 12:00:00 PM
- Incannex approves 1-for-30 reverse stock split to regain Nasdaq compliance • IH Market News • 02/25/2026 03:26:23 PM
- Incannex Announces Reverse Stock Split • GlobeNewswire Inc. • 02/25/2026 02:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 01:00:33 PM
- Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026 • Newsfile • 02/18/2026 11:35:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2026 12:48:45 PM
